ECSP19073317A - Combinación farmacéutica que comprende ponesimod - Google Patents

Combinación farmacéutica que comprende ponesimod

Info

Publication number
ECSP19073317A
ECSP19073317A ECSENADI201973317A ECDI201973317A ECSP19073317A EC SP19073317 A ECSP19073317 A EC SP19073317A EC SENADI201973317 A ECSENADI201973317 A EC SENADI201973317A EC DI201973317 A ECDI201973317 A EC DI201973317A EC SP19073317 A ECSP19073317 A EC SP19073317A
Authority
EC
Ecuador
Prior art keywords
ponesimod
pharmaceutical combination
combination including
active ingredient
teriflunomide
Prior art date
Application number
ECSENADI201973317A
Other languages
English (en)
Inventor
Laetitia Pouzol
Martine Clozel
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of ECSP19073317A publication Critical patent/ECSP19073317A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente invención se relaciona con una combinación farmacéutica que comprende un primer ingrediente activo que es ponesimod y un segundo ingrediente activo que se selecciona del grupo que consiste en teriflunomida y leflunomida.
ECSENADI201973317A 2017-03-14 2019-10-10 Combinación farmacéutica que comprende ponesimod ECSP19073317A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2017055994 2017-03-14

Publications (1)

Publication Number Publication Date
ECSP19073317A true ECSP19073317A (es) 2019-11-30

Family

ID=61655772

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201973317A ECSP19073317A (es) 2017-03-14 2019-10-10 Combinación farmacéutica que comprende ponesimod

Country Status (24)

Country Link
US (2) US11723896B2 (es)
EP (1) EP3595657A1 (es)
JP (3) JP7281406B2 (es)
KR (1) KR102574562B1 (es)
CN (1) CN110381942B (es)
AU (2) AU2018233109B2 (es)
BR (1) BR112019018894A2 (es)
CA (1) CA3056301C (es)
CL (1) CL2019002525A1 (es)
CO (1) CO2019008510A2 (es)
CR (1) CR20190464A (es)
DO (1) DOP2019000257A (es)
EA (1) EA201992117A1 (es)
EC (1) ECSP19073317A (es)
IL (1) IL269239B2 (es)
JO (1) JOP20190207A1 (es)
MA (1) MA49822A (es)
MX (1) MX390941B (es)
NI (1) NI201900092A (es)
PE (1) PE20191489A1 (es)
PH (1) PH12019502110A1 (es)
SG (1) SG11201907308UA (es)
UA (1) UA125756C2 (es)
WO (1) WO2018167030A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL178596C (nl) 1975-06-05 1986-04-16 Hoechst Ag Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
DE2854439A1 (de) 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
KR20020072312A (ko) 2000-02-15 2002-09-14 테바 파마슈티컬 인더스트리즈 리미티드 레플루노미드를 합성하는 방법
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
DK1381356T3 (da) * 2001-04-05 2008-09-22 Aventis Pharma Inc Anvendelse af (z)-z-cyano-3-hydroxy-but-2-enoinsyre-(4-trifluoromethylphenyl) - amide til behandling af multipel sclerose
US6894184B2 (en) 2003-03-18 2005-05-17 Aventis Pharma Deutschland Gmbh Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
AU2004295047B2 (en) 2003-11-21 2011-03-10 Laboratoires Juvise Pharmaceuticals 5-(benz- (Z) -ylidene) -thiazolidin-4-one derivatives as immunosuppressant agents
SG142305A1 (en) * 2004-10-19 2008-05-28 Aventis Pharma Inc Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'- trifluoromethylphenyl)-amide for treating inflammatory bowel disease
DE102006017896A1 (de) 2006-04-13 2007-10-25 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Leflunomid enthaltende pharmazeutische Zusammensetzungen
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
DK2489662T3 (da) 2006-11-23 2014-10-20 Actelion Pharmaceuticals Ltd Mellemprodukter af en ny fremgangsmåde til fremstillingen af 5-benzyliden-2-alkylimino-3-phenylthiazolidin-4-on derivater
DK2278960T4 (da) * 2008-03-17 2020-01-27 Actelion Pharmaceuticals Ltd Dosisregimen til en selektiv sip1 receptoragonist
GB0819182D0 (en) 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
MX336663B (es) 2009-09-18 2016-01-27 Sanofi Sa Formulaciones en comprimido de la (4'-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada.
WO2012015758A2 (en) 2010-07-30 2012-02-02 Saint Louis University Methods of treating pain
AR082436A1 (es) 2010-08-02 2012-12-05 Sanofi Aventis Us Llc Uso de teriflunomida para tratar la esclerosis multiple
EP2692343A1 (en) * 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
HRP20200883T1 (hr) 2012-08-17 2020-09-04 Actelion Pharmaceuticals Ltd. Postupak za pripremanje (2z,5z)-5-(3-kloro-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona i međuproizvodi koji se koriste u navedenom postupku
WO2016079687A1 (en) 2014-11-18 2016-05-26 Lupin Limited Oral pharmaceutical composition of teriflunomide
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
EA036075B1 (ru) * 2014-12-11 2020-09-23 Актелион Фармасьютиклз Лтд Схема дозирования для селективного агониста рецептора s1p1
CN107920991A (zh) 2015-06-18 2018-04-17 马丁尼斯生物制药纳米技术公司 治疗炎性疾病或病状的组合物和方法
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود

Also Published As

Publication number Publication date
JP7281406B2 (ja) 2023-05-25
IL269239A (en) 2019-11-28
CA3056301C (en) 2024-10-01
AU2023274118A1 (en) 2023-12-21
IL269239B2 (en) 2023-07-01
MX2019010874A (es) 2019-12-11
US20200069655A1 (en) 2020-03-05
AU2018233109A1 (en) 2019-08-22
CO2019008510A2 (es) 2019-10-21
KR102574562B1 (ko) 2023-09-04
CL2019002525A1 (es) 2020-02-07
MA49822A (fr) 2020-06-17
AU2023274118B2 (en) 2024-12-12
DOP2019000257A (es) 2020-09-15
JP2020510045A (ja) 2020-04-02
BR112019018894A2 (pt) 2020-04-14
CN110381942A (zh) 2019-10-25
US11723896B2 (en) 2023-08-15
MX390941B (es) 2025-03-21
NI201900092A (es) 2020-03-11
CN110381942B (zh) 2022-12-27
IL269239B1 (en) 2023-03-01
US20240139161A1 (en) 2024-05-02
EA201992117A1 (ru) 2020-02-17
JP2024096962A (ja) 2024-07-17
KR20190122716A (ko) 2019-10-30
PE20191489A1 (es) 2019-10-21
JP2023030091A (ja) 2023-03-07
UA125756C2 (uk) 2022-06-01
CA3056301A1 (en) 2018-09-20
PH12019502110A1 (en) 2020-03-16
EP3595657A1 (en) 2020-01-22
CR20190464A (es) 2019-11-26
JOP20190207A1 (ar) 2019-09-10
WO2018167030A1 (en) 2018-09-20
US12527772B2 (en) 2026-01-20
AU2018233109B2 (en) 2023-09-28
SG11201907308UA (en) 2019-09-27

Similar Documents

Publication Publication Date Title
ECSP19073317A (es) Combinación farmacéutica que comprende ponesimod
MX2020006150A (es) Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas.
MX2018012486A (es) Composiciones para aplicacion topica de compuestos.
CR20170099A (es) Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas
MX2017015579A (es) Formas de dosificacion solidas de palbociclib.
EP3725321A4 (en) COMPOSITION WITH A BACTERIUM OF THE GENUS BIFIDOBACTERIUM AS THE ACTIVE SUBSTANCE
EA202090183A1 (ru) Композиции, способы и получение дейтерированного домперидона
CY1124041T1 (el) Συνθεσεις που περιλαμβανουν κυκλοσπορινη
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
IL266279B1 (en) Stable aqueous capsaicin injectable formuatlions and medical uses thereof
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
UY37560A (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
UY36273A (es) Composicion para el tratamiento de neuropatías y del dolor neuropático
CL2018000282A1 (es) Amida seleccionada de ácido gamma-hidroxibutírico y usos de la misma en el tratamiento de abuso de alcohol
MX373197B (es) Formulaciones estables de undecanoato de testosterona.
MX388400B (es) Una composición de dos componentes, que comprende ácido acetilsalicílico.
CO2017001076A2 (es) Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam
CL2019000144A1 (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos.
CY1122979T1 (el) Φαρμακευτικη συνθεση για τη θεραπεια της μυκητιασης
CO2019007261A2 (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
EA201792093A1 (ru) 2-тиопиримидиноны
EA201990162A1 (ru) Фармацевтические композиции
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
MX2020004731A (es) Terapias de combinacion de inhibidor ezh2.
CL2016003273A1 (es) Composiciones antimicrobianas con agentes efervescentes